Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (DE:COJ0)
FRANKFURT:COJ0
COJ0 Stock Chart & Stats
€0.17
>-€0.01(-5.52%)
At close: 4:00 PM EST
€0.17
>-€0.01(-5.52%)
Day’s Range― - ―
52-Week Range€0.10 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.22M
Enterprise Value-€29.00M
Total Cash (Recent Filing)€73.75M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding19,801,197
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.66
Price to Sales (P/S)144.56
P/FCF Ratio-1.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.
Gene-Therapy FocusThe focus on gene-therapy for neurological diseases positions the company in a high-potential market with growing demand for innovative treatments.
Cash Flow TrackingClose tracking of cash flow to net income indicates efficient cash management, which is crucial for sustaining operations during loss-making periods.
Bears Say
Revenue DeclineA sharp decline in revenue indicates challenges in maintaining sales momentum, which could hinder long-term growth and market competitiveness.
Sustained Cash BurnSustained cash burn reflects ongoing financial strain, potentially limiting the company's ability to invest in R&D and future growth initiatives.
Equity DeclineA decline in equity suggests value erosion, which could impact investor confidence and the company's ability to raise capital in the future.
COJ0 FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was €0.10 and its highest was €0.24 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is €4.22M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Aug 21, 2026 which is in 185 days.
How were CombiGene AB’s earnings last quarter?
CombiGene AB released its earnings results on Feb 13, 2026. The company reported <€0.001 earnings per share for the quarter, beating the consensus estimate of N/A by <€0.001.
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB does not currently pay dividends.
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
CombiGene AB reported an EPS of <€0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.183%.
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in DE:COJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CombiGene AB
Lärkberget AB (publ) operates as an investment company. It is involved in Direct investments in low-risk instruments; Financial investments; Direct investments in unlisted profitable companies; and Reverse acquisition platform. The company was formerly known as CombiGene AB (publ) and changed its name to Lärkberget AB (publ) in June 2025. Lärkberget AB (publ) was incorporated in 1990 and is based in Östermalm, Sweden.
Technical Analysis
2cureX AB
―
Stayble Therapeutics AB
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―